CytomX Book Value Per Share from 2010 to 2025

CTMX Stock

USD 0.62 0.03 5.08%

CytomX Therapeutics Book Value Per Share yearly trend continues to be fairly stable with very little volatility. Book Value Per Share is likely to outpace its year average in 2025. Book Value Per Share is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of CytomX Therapeutics according to its financial statements. View All Fundamentals

Book Value Per Share

First Reported

2010-12-31

Previous Quarter

(0.01)

Current Value

(0.01)

Quarterly Volatility

3.95680729

Credit Downgrade

Yuan Drop

Covid

Check CytomX Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among CytomX Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 2.3 M, Interest Expense of 2.1 M or Selling General Administrative of 29.1 M, as well as many indicators such as Price To Sales Ratio of 0.6, Dividend Yield of 0.0299 or Days Sales Outstanding of 7.79. CytomX financial statements analysis is a perfect complement when working with CytomX Therapeutics Valuation or Volatility modules.

Check out the analysis of CytomX Therapeutics Correlation against competitors.

For more information on how to buy CytomX Stock please use our How to Invest in CytomX Therapeutics guide.

Latest CytomX Therapeutics' Book Value Per Share Growth Pattern

Below is the plot of the Book Value Per Share of CytomX Therapeutics over the last few years. It is the ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements. CytomX Therapeutics' Book Value Per Share historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in CytomX Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported (0.01) X

10 Years Trend

Very volatile

Compare to Others All Fundamentals

Book Value Per Share

Timeline

CytomX Book Value Per Share Regression Statistics

	Arithmetic Mean	1.01
	Coefficient Of Variation	391.35
	Mean Deviation	2.30
	Median	(0.01)
	Standard Deviation	3.96
	Sample Variance	15.66
	Range	16.916
	R-Value	(0)
	Mean Square Error	16.77
	R-Squared	0.000018
	Significance	0.99
	Slope	(0)
	Total Sum of Squares	234.84

CytomX Book Value Per Share History

	2025	-0.00513
	2024	-0.0054
	2023	-0.64
	2022	-1.3
	2021	1.39
	2020	1.08
	2019	1.13

Other Fundumenentals of CytomX Therapeutics

Tangible Book Value Per Share

CytomX Therapeutics Book Value Per Share component correlations

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Short Term Investments	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment	Net Tangible Assets	Deferred Long Term Liab	Short Long Term Debt	Capital Surpluse	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		0.69	0.52	-0.92	-0.41	0.7	0.18	0.19	0.87	0.85	1.0	0.56	-0.31	0.19	0.42	0.84	0.66	0.19	0.42	0.1	-0.06	0.19
Total Stockholder Equity	0.69		-0.04	-0.6	0.01	0.77	-0.33	0.07	0.64	0.28	0.71	0.76	0.08	0.07	0.23	0.91	0.24	0.07	0.02	0.54	0.26	0.07
Current Deferred Revenue	0.52	-0.04		-0.37	-0.93	0.04	0.54	-0.15	0.6	0.74	0.49	0.03	-0.89	-0.15	0.26	0.31	0.81	-0.15	0.88	-0.72	-0.79	-0.15
Net Debt	-0.92	-0.6	-0.37		0.27	-0.69	-0.29	-0.26	-0.66	-0.8	-0.92	-0.46	0.16	-0.26	-0.36	-0.73	-0.52	-0.26	-0.31	-0.2	-0.1	-0.26
Retained Earnings	-0.41	0.01	-0.93	0.27		0.05	-0.45	0.46	-0.52	-0.64	-0.38	0.01	0.97	0.46	-0.33	-0.3	-0.88	0.46	-0.95	0.72	0.93	0.46
Accounts Payable	0.7	0.77	0.04	-0.69	0.05		0.05	0.33	0.58	0.37	0.71	0.82	0.19	0.33	0.26	0.83	0.09	0.33	-0.09	0.31	0.33	0.33
Net Receivables	0.18	-0.33	0.54	-0.29	-0.45	0.05		-0.02	0.2	0.47	0.18	0.05	-0.37	-0.02	-0.05	0.01	0.32	-0.02	0.35	-0.7	-0.39	-0.02
Good Will	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02		-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Short Term Investments	0.87	0.64	0.6	-0.66	-0.52	0.58	0.2	-0.06		0.78	0.88	0.7	-0.4	-0.06	0.28	0.83	0.7	-0.06	0.43	-0.11	-0.26	-0.06
Total Liab	0.85	0.28	0.74	-0.8	-0.64	0.37	0.47	-0.03	0.78		0.84	0.26	-0.52	-0.03	0.43	0.53	0.82	-0.03	0.58	-0.27	-0.37	-0.03
Total Current Assets	1.0	0.71	0.49	-0.92	-0.38	0.71	0.18	0.2	0.88	0.84		0.6	-0.28	0.2	0.38	0.85	0.64	0.2	0.39	0.13	-0.03	0.2
Short Term Debt	0.56	0.76	0.03	-0.46	0.01	0.82	0.05	0.04	0.7	0.26	0.6		0.12	0.04	-0.07	0.8	0.15	0.04	-0.09	0.24	0.2	0.04
Intangible Assets	-0.31	0.08	-0.89	0.16	0.97	0.19	-0.37	0.43	-0.4	-0.52	-0.28	0.12		0.43	-0.27	-0.19	-0.83	0.43	-0.98	0.7	0.93	0.43
Common Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43		-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62	1.0
Property Plant Equipment	0.42	0.23	0.26	-0.36	-0.33	0.26	-0.05	-0.07	0.28	0.43	0.38	-0.07	-0.27	-0.07		0.28	0.45	-0.07	0.32	-0.09	-0.24	-0.07
Net Tangible Assets	0.84	0.91	0.31	-0.73	-0.3	0.83	0.01	0.06	0.83	0.53	0.85	0.8	-0.19	0.06	0.28		0.45	0.06	0.29	0.2	0.0	0.06
Deferred Long Term Liab	0.66	0.24	0.81	-0.52	-0.88	0.09	0.32	-0.44	0.7	0.82	0.64	0.15	-0.83	-0.44	0.45	0.45		-0.44	0.85	-0.42	-0.72	-0.44
Short Long Term Debt	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44		-0.32	0.32	0.62	1.0
Capital Surpluse	0.42	0.02	0.88	-0.31	-0.95	-0.09	0.35	-0.32	0.43	0.58	0.39	-0.09	-0.98	-0.32	0.32	0.29	0.85	-0.32		-0.59	-0.84	-0.32
Net Invested Capital	0.1	0.54	-0.72	-0.2	0.72	0.31	-0.7	0.32	-0.11	-0.27	0.13	0.24	0.7	0.32	-0.09	0.2	-0.42	0.32	-0.59		0.83	0.32
Net Working Capital	-0.06	0.26	-0.79	-0.1	0.93	0.33	-0.39	0.62	-0.26	-0.37	-0.03	0.2	0.93	0.62	-0.24	0.0	-0.72	0.62	-0.84	0.83		0.62
Capital Stock	0.19	0.07	-0.15	-0.26	0.46	0.33	-0.02	1.0	-0.06	-0.03	0.2	0.04	0.43	1.0	-0.07	0.06	-0.44	1.0	-0.32	0.32	0.62

Click cells to compare fundamentals

About CytomX Therapeutics Financial Statements

CytomX Therapeutics investors use historical fundamental indicators, such as CytomX Therapeutics' Book Value Per Share, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in CytomX Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Book Value Per Share	(0.01)	(0.01)
Tangible Book Value Per Share	(0.02)	(0.02)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for CytomX Stock Analysis

When running CytomX Therapeutics' price analysis, check to measure CytomX Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CytomX Therapeutics is operating at the current time. Most of CytomX Therapeutics' value examination focuses on studying past and present price action to predict the probability of CytomX Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CytomX Therapeutics' price. Additionally, you may evaluate how the addition of CytomX Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC